-
Mashup Score: 12PARP Inhibitors for Breast Cancer Treatment - 9 day(s) ago
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research directions.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12PARP Inhibitors for Breast Cancer Treatment - 10 day(s) ago
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research directions.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21
Summary. Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4–directed antibody–drug conjugate.See related article by Gitto et al., p. 1567
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone re ceptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the US Food and Drug Administration (FDA) action date for its regulatory decision, is during
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Resources for Patients with Brain Metastasis | Breast Cancer Brain Mets | Leptomeningeal Disease (LMD) | MBCBrainmets.org - 1 month(s) ago
As a one-stop resource hub for breast cancer patients living with brain metastasis, we are committed to sharing cutting-edge information and resources in a simple format. Curated by fellow patients and supported by nonprofit funding, our mission is to connect you to knowledge and support tailored specifically to your needs.
Source: MBCBrainmets.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Resources for Patients with Brain Metastasis | Breast Cancer Brain Mets | Leptomeningeal Disease (LMD) | MBCBrainmets.org - 1 month(s) ago
As a one-stop resource hub for breast cancer patients living with brain metastasis, we are committed to sharing cutting-edge information and resources in a simple format. Curated by fellow patients and supported by nonprofit funding, our mission is to connect you to knowledge and support tailored specifically to your needs.
Source: MBCBrainmets.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10PARP Inhibitors for Breast Cancer Treatment - 2 month(s) ago
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research directions.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors - OncoDaily - 3 month(s) ago
Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors / Albert Grinshpun, cancer, OncoDaily, Oncology, Paolo Tarantino, Ribociclib
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
RT @npriedig: PARP Inhibitors for Breast Cancer Treatment https://t.co/us89qbhyHv